Pomalidomide grindeks

Package leaflet: Information for the patient

Pomalidomide Grindeks, 1 mg, hard capsules
Pomalidomide Grindeks, 2 mg, hard capsules
Pomalidomide Grindeks, 3 mg, hard capsules
Pomalidomide Grindeks, 4 mg, hard capsules
Pomalidomide
Pomalidomide Grindeks is expected to cause severe birth defects and may result in fetal death.

• Do not take this medicine if you are pregnant or may become pregnant.
• You must follow the contraceptive advice provided in this leaflet.

Please read this leaflet carefully before taking this medicine, as it contains important information for you.

• Keep this leaflet so that you can read it again if needed.
• If you have any questions, please consult your doctor or pharmacist.
• This medicine has been prescribed for a specific individual. Do not give it to others. It may harm other people, even if their symptoms are the same as yours.
• If you experience any adverse reactions, including any not listed in this leaflet, inform your doctor or pharmacist. See section 4.

Contents of the leaflet

1. What Pomalidomide Grindeks is and what it is used for
2. Important information before taking Pomalidomide Grindeks
3. How to take Pomalidomide Grindeks
4. Possible side effects
5. How to store Pomalidomide Grindeks
6. Contents of the pack and other information

1. What Pomalidomide Grindeks is and what it is used for

Pomalidomide Grindeks contains the active substance pomalidomide. This medicine is similar to thalidomide and belongs to a group of medicines that affect the immune system (the body's natural defenses).

What Pomalidomide Grindeks is used for
Pomalidomide Grindeks is used to treat adults with a type of cancer called multiple myeloma.
Pomalidomide Grindeks is used in combination with:

• two other medicines, bortezomib (a chemotherapy agent) and dexamethasone (an anti-inflammatory medicine), in patients who have previously received at least one other treatment regimen containing lenalidomide

or

• one other medicine, dexamethasone, in patients with multiple myeloma whose disease has worsened despite having previously received at least two treatment regimens containing lenalidomide and bortezomib.

What is multiple myeloma
Multiple myeloma is a cancer that affects a certain type of blood cell (called plasma cells). These cells grow uncontrollably and accumulate in the bone marrow, leading to bone and kidney damage.
Multiple myeloma is generally considered incurable. However, treatment may relieve the signs and symptoms of the disease or cause them to subside for a period of time—this is known as a "response" to treatment.

How Pomalidomide Grindeks works
Pomalidomide Grindeks works in several different ways:

• by inhibiting the growth of myeloma cells,
• by stimulating the immune system to attack cancer cells,
• by inhibiting the formation of blood vessels that supply tumor cells.

Benefits of using Pomalidomide Grindeks with bortezomib and dexamethasone
When used in combination with bortezomib and dexamethasone in patients who have previously received at least one other treatment, Pomalidomide Grindeks can slow the progression of multiple myeloma.
Pomalidomide Grindeks in combination with bortezomib and dexamethasone typically delayed the recurrence of multiple myeloma for up to 11 months—compared to 7 months in patients receiving only bortezomib and dexamethasone.

Benefits of using Pomalidomide Grindeks with dexamethasone
When used in combination with dexamethasone in patients who have previously received at least two other treatments, Pomalidomide Grindeks can slow the progression of multiple myeloma.
Pomalidomide Grindeks in combination with dexamethasone typically delayed the recurrence of multiple myeloma for up to 4 months—compared to 2 months in patients receiving dexamethasone alone.

2. Important information before using Pomalidomide Grindeks

When not to take Pomalidomide Grindeks

• if the patient is pregnant, suspects she may be pregnant, or plans to become pregnant, because Pomalidomide Grindeks is expected to be harmful to the fetus (men and women taking this medicine must read the section "Pregnancy, contraception and breastfeeding – information for women and men" below).
• if the patient could become pregnant, unless she uses all necessary methods of contraception (see section "Pregnancy, contraception and breastfeeding – information for women and men"). If the patient could become pregnant, the doctor will always confirm during each prescription that the patient understands all necessary contraceptive measures she must use, and will provide written confirmation to the patient.
• if the patient is allergic to pomalidomide or any of the other ingredients of this medicine listed in section 6). If an allergic reaction to the medicine is suspected, medical advice should be sought.

If the patient is unsure whether any of the above situations apply, please consult a doctor, pharmacist, or nurse before starting treatment with Pomalidomide Grindeks.

Warnings and precautions

Before starting treatment with Pomalidomide Grindeks, discuss with your doctor, pharmacist, or nurse if:

• the patient has ever had blood clots in the past. Treatment with Pomalidomide Grindeks increases the risk of developing blood clots in veins and arteries. The doctor may prescribe additional treatment (e.g. warfarin) or reduce the dose of Pomalidomide Grindeks to lower the risk of blood clots.
• the patient has ever experienced hypersensitivity reactions such as rash, itching, swelling, dizziness, or breathing difficulties while taking similar medicines called "thalidomide" or "lenalidomide".
• the patient has had a heart attack, has heart failure, experiences breathing difficulties, or if the patient smokes, has high blood pressure, or high cholesterol levels.
• the patient has extensive tumour involvement in the body, including in the bone marrow. This may lead to a condition where tumours break down rapidly, causing abnormal levels of chemical substances in the blood, which may result in kidney failure. The patient may also experience irregular heartbeats. This condition is known as tumour lysis syndrome.
• the patient has or has had neuropathy (nerve damage causing tingling or pain in hands or feet).
• the patient has or has had hepatitis B virus infection. Taking Pomalidomide Grindeks may reactivate the virus in previously infected patients, leading to a recurrence of infection. The doctor should check whether the patient has been previously infected with hepatitis B virus.
• the patient has or has previously experienced any combination of the following symptoms: facial rash or widespread rash, redness of the skin, high fever, flu-like symptoms, swollen lymph nodes (observed symptoms of a severe skin reaction known as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) or "drug hypersensitivity syndrome", toxic epidermal necrolysis (TEN), or Stevens-Johnson syndrome (SJS); see also section 4 "Possible side effects").

It should be emphasized that patients with multiple myeloma treated with pomalidomide may develop secondary cancers. Therefore, the treating physician should carefully evaluate the benefits and risks associated with prescribing this medicine.

At any time during or after completion of treatment, immediately inform the doctor or nurse if any of the following occur: vision disturbances, loss of vision, double vision, difficulty speaking, weakness in arms or legs, changes in walking or balance problems, persistent numbness, reduced sensation, loss of sensation, memory loss, or disorientation. All these symptoms may indicate a serious and potentially fatal brain disorder called progressive multifocal leukoencephalopathy. If these symptoms occurred before starting treatment with Pomalidomide Grindeks, inform the doctor about any changes in these symptoms.

After treatment ends, the patient should return all unused capsules to the pharmacy.

Pregnancy, contraception and breastfeeding – information for women and men

As indicated below, the conditions of the pregnancy prevention programme must be strictly followed during treatment with Pomalidomide Grindeks. Women taking Pomalidomide Grindeks must not become pregnant, and men being treated with pomalidomide must not allow their female partner to become pregnant, because this medicine is expected to harm the unborn child. The patient and his/her partner must use effective methods of contraception during treatment with this medicine.

Women

Do not take Pomalidomide Grindeks if you are pregnant, suspect you may be pregnant, or plan to become pregnant, because this medicine is expected to harm the unborn child. Before starting treatment, the patient must inform the treating doctor if she could become pregnant, even if she considers it unlikely.

If the patient could become pregnant:

• must use effective methods of contraception for at least 4 weeks before starting treatment, throughout the entire treatment period, and for at least 4 weeks after treatment ends. The patient should discuss with her doctor which method of contraception is best for her.

• at each prescription, the treating doctor will confirm that the patient understands all necessary contraceptive measures she must use to prevent pregnancy.

• the treating doctor will order pregnancy tests before treatment, no less frequently than every 4 weeks during treatment, and at least 4 weeks after treatment ends.

If the patient becomes pregnant despite using preventive methods:

• must immediately stop treatment and inform the treating doctor without delay.

Breastfeeding

It is not known whether Pomalidomide Grindeks passes into human milk. If the patient is breastfeeding or intends to breastfeed, she must inform the treating doctor. The treating doctor will advise whether she should stop or continue breastfeeding.

Men

Pomalidomide Grindeks passes into human semen.

• If the male patient's partner is pregnant or could become pregnant, the man must use condoms throughout the entire treatment period and for 7 days after treatment ends.
• If the female partner of a man being treated with Pomalidomide Grindeks becomes pregnant, the doctor must be informed immediately. The partner should seek medical advice without delay. The patient must not donate sperm or semen during treatment and for 7 days after treatment ends.

Blood donation and blood tests

During treatment and for 7 days after treatment ends, the patient must not donate blood.

Before and during treatment with Pomalidomide Grindeks, regular blood tests will be performed. This is because the medicine may reduce the number of blood cells (white blood cells) that help fight infections, and reduce the number of platelets that help stop bleeding.

The treating doctor should schedule blood tests:

• before treatment begins,
• weekly during the first 8 weeks of treatment,
• thereafter at least once a month for as long as the patient is taking Pomalidomide Grindeks.

The treating doctor may adjust the dose of Pomalidomide Grindeks or discontinue treatment based on blood test results. The treating doctor may also adjust the dose or discontinue treatment due to the patient's overall health condition.

Children and adolescents

Pomalidomide Grindeks is not recommended for use in children and adolescents under 18 years of age.

Pomalidomide Grindeks and other medicines

Inform your doctor or pharmacist about all medicines you are currently taking, have recently taken, or plan to take, because Pomalidomide Grindeks may affect the action of other medicines. Other medicines may also affect the action of Pomalidomide Grindeks.

Before taking Pomalidomide Grindeks, inform the doctor, pharmacist, or nurse, especially if the patient is taking any of the following medicines:

• certain antifungal medicines such as ketoconazole,
• certain antibiotics (e.g. ciprofloxacin, enoxacin),
• certain antidepressants such as fluvoxamine.

Driving and using machines

While taking Pomalidomide Grindeks, some people may experience fatigue, dizziness, fainting, disorientation, or reduced alertness. If such symptoms occur, the patient should not drive, operate tools, or use machinery.

Pomalidomide Grindeks

The medicine contains less than 1 mmol (23 mg) of sodium per capsule, meaning it is considered "sodium-free".

Pomalidomide Grindeks contains azo dyes

The capsules contain azo dyes: brilliant black PN (all strengths), azorubine (carmoisine) (all strengths), and orange-yellow FCF (only 2 mg capsules). These dyes may cause allergic reactions.

3. How to take Pomalidomide Grindeks

Pomalidomide Grindeks must be prescribed by a physician experienced in the treatment of multiple myeloma.
This medicine should always be taken exactly as prescribed by your doctor. If you have any doubts, consult your doctor, pharmacist, or nurse.

When to take Pomalidomide Grindeks with other medicines

Pomalidomide Grindeks with bortezomib and dexamethasone

• Read the package leaflets provided with bortezomib and dexamethasone for further information on their use and effects.
• Pomalidomide Grindeks, bortezomib, and dexamethasone are administered in treatment cycles. Each cycle lasts 21 days (3 weeks).
• The table below shows which medicines should be taken on each day of the 3-week cycle:
  o Find the correct day in the table and check which medicines should be taken.
  o On some days, all three medicines are taken; on other days, only two or one medicine is taken, and on some days no medicines are taken.

PMD: Pomalidomide Grindeks; BOR: bortezomib; DEX: dexamethasone
Cycles 1 to 8 Cycle 9 and onwards
Medicine Medicine
Day PMD BOR DEX Day PMD BOR DEX
1 √ √ √ 1 √ √ √
2 √ √ 2 √ √
3 √ 3 √
4 √ √ √ 4 √
5 √ √ 5 √
6 √ 6 √
7 √ 7 √
8 √ √ √ 8 √ √ √
9 √ √ 9 √ √
10 √ 10 √
11 √ √ √ 11 √
12 √ √ 12 √
13 √ 13 √
14 √ 14 √
15 15
16 16
17 17
18 18
19 19
20 20
21 21

After completing each 3-week cycle, begin a new cycle.

Pomalidomide Grindeks with dexamethasone only

• Read the package leaflet provided with dexamethasone for further information on its use and effects.
• Pomalidomide Grindeks and dexamethasone are administered in treatment cycles. Each cycle lasts 28 days (4 weeks).
• The table below shows which medicines should be taken on each day of the 4-week cycle:
  o Find the correct day in the table and check which medicines should be taken.
  o On some days, both medicines are taken; on other days, only one medicine is taken, and on some days no medicines are taken.

PMD: Pomalidomide Grindeks; DEX: dexamethasone
Medicine
Day PMD DEX
1 √ √
2 √
3 √
4 √
5 √
6 √
7 √
8 √ √
9 √
10 √
11 √
12 √
13 √
14 √
15 √ √
16 √
17 √
18 √
19 √
20 √
21 √
22 √

After completing each 4-week cycle, begin a new cycle.

What dose of Pomalidomide Grindeks should be taken with other medicines

Pomalidomide Grindeks with bortezomib and dexamethasone

• The recommended starting dose of Pomalidomide Grindeks is 4 mg once daily.
• The recommended starting dose of bortezomib will be determined by the doctor based on the patient's height and body weight (1.3 mg/m² body surface area).
• The recommended starting dose of dexamethasone is 20 mg once daily. However, if the patient is over 75 years of age, the recommended starting dose is 10 mg once daily.

Pomalidomide Grindeks with dexamethasone only

• The recommended dose of Pomalidomide Grindeks is 4 mg once daily.
• The recommended starting dose of dexamethasone is 40 mg once daily. However, if the patient is over 75 years of age, the recommended starting dose is 20 mg once daily.

Your doctor may reduce the dose of Pomalidomide Grindeks, bortezomib, or dexamethasone, or discontinue treatment with one or more of these medicines, depending on blood test results, the patient's general health, concomitant use of other medicines (e.g. ciprofloxacin, enoxacin, and fluvoxamine), and if treatment-related adverse reactions occur (especially rash and swelling).

If the patient has liver or kidney disease, the treating physician will closely monitor the patient's health during treatment.

How to take Pomalidomide Grindeks

• Do not break, open, or chew the capsules. If powder from a damaged capsule comes into contact with the skin, wash the skin immediately and thoroughly with soap and water.
• Healthcare professionals, caregivers, and family members should wear disposable gloves when handling the blister pack or capsule. Gloves should then be carefully removed to avoid skin exposure, placed in a sealed polyethylene plastic bag, and disposed of according to local regulations. Hands should then be washed thoroughly with soap and water. Pregnant women or women who suspect they may be pregnant should not handle the blister pack or capsule.
• Swallow the capsules whole, preferably with water.
• The capsules may be taken with or without food.
• Pomalidomide Grindeks should be taken approximately at the same time each day.

To remove a capsule from the blister, press only on one end of the capsule and push it through the foil. Do not press on the center of the capsule, as this may damage it.

If the patient has kidney problems and is on dialysis, the treating physician will advise how and when to take Pomalidomide Grindeks.

Duration of treatment with Pomalidomide Grindeks

Continue treatment cycles until the doctor decides to discontinue therapy.

If you take more Pomalidomide Grindeks than prescribed

If you take more than the prescribed dose, contact your doctor immediately or go to the nearest hospital. Take the medicine packaging with you.

If you miss a dose of Pomalidomide Grindeks

If you miss a dose of Pomalidomide Grindeks on the day it should have been taken, take the next capsule at the usual time the following day. Do not take a double dose to make up for the missed capsule.

If you have any further questions about the use of this medicine, consult your doctor or pharmacist.

4. Possible adverse effects

Like all medicines, this medicine can cause adverse effects, although not everyone will experience them.
Serious adverse effects
If any of the following serious adverse effects occur, stop taking Pomalidomide Grindeks
immediately and contact a doctor straight away – immediate treatment may be necessary.

• Fever, chills, sore throat, cough, mouth ulcers or any other signs of infection (due to reduced numbers of white blood cells, which help fight infection).
• Unexplained bleeding or bruising, including nosebleeds, or bleeding from the intestines or stomach (due to the medicine’s effect on blood cells called platelets).
• Rapid breathing, fast heartbeat, fever and chills, passing very little or no urine, nausea and vomiting, confusion, loss of consciousness (due to a blood infection called sepsis or septic shock).
• Severe, persistent or bloody diarrhoea (also with abdominal pain or fever) caused by bacteria called Clostridium difficile.
• Chest pain or leg pain and swelling, particularly in the calf (due to blood clots).
• Shallow breathing (due to severe chest infections, pneumonia, heart failure or blood clots).
• Swelling of the face, lips, tongue and throat, possibly causing breathing difficulties (due to severe allergic reactions known as angioedema and anaphylactic reaction).
• Certain types of skin cancer (squamous cell carcinoma and basal cell carcinoma), which may cause changes in the appearance of the skin or the development of skin growths. If the patient notices any skin changes while taking Pomalidomide Grindeks, this should be reported to a doctor as soon as possible.
• Reactivation of hepatitis B virus infection, which may cause yellowing of the skin and whites of the eyes, dark-coloured urine, pain in the right side of the abdomen, fever, nausea and vomiting. Seek medical advice immediately if these symptoms occur.
• Widespread rash, high fever, swollen lymph nodes and involvement of other organs (drug reaction with eosinophilia and systemic symptoms, also known as DRESS or drug hypersensitivity syndrome, toxic epidermal necrolysis or Stevens-Johnson syndrome). If any of these symptoms occur, stop taking pomalidomide immediately and contact a doctor or seek immediate medical help. See also section 2.

If any of the above serious adverse effects occur, stop taking Pomalidomide Grindeks
immediately and contact a doctor straight away – immediate treatment may be necessary.
Other adverse effects
Very common (may affect more than 1 in 10 people):

• Shortness of breath (dyspnoea).
• Lung infections (pneumonia and bronchitis).
• Bacterial or viral infections of the nose, sinuses and throat.
• Influenza-like symptoms (flu).
• Reduced number of red blood cells, which may lead to anaemia causing fatigue and weakness.
• Low blood potassium levels (hypokalaemia), which may cause weakness, muscle cramps, muscle pain, palpitations, tingling or numbness, shortness of breath, mood changes.
• High blood sugar levels.
• Fast and irregular heartbeat (atrial fibrillation).
• Loss of appetite.
• Constipation, diarrhoea or nausea.
• Vomiting.
• Abdominal pain.
• Lack of energy.
• Difficulty falling asleep or staying asleep.
• Dizziness, tremor.
• Muscle cramps, muscle weakness.
• Bone pain, back pain.
• Numbness, tingling or burning sensation of the skin, pain in hands or feet (sensory peripheral neuropathy).
• Swelling of the body, including hands and feet.
• Rash.
• Urinary tract infection, which may cause burning when passing urine or a need to pass urine more frequently.

Common (may affect up to 1 in 10 people):

• Fainting.
• Bleeding within the skull.
• Reduced ability to move or feel in the hands, arms, feet and legs due to nerve damage (sensory-motor peripheral neuropathy).
• Numbness, itching and tingling of the skin (paresthesia).
• A spinning sensation in the head making it difficult to maintain proper standing posture and normal movement.
• Swelling caused by fluid accumulation.
• Urticaria (hives).
• Rash.
• Itching of the skin.
• Shingles (herpes zoster).
• Heart attack (chest pain spreading to arms, neck, jaw, feeling of sweating and breathlessness, nausea or vomiting).
• Chest pain, infection in the chest area.
• Increased blood pressure.
• Simultaneous reduction in the number of red blood cells, white blood cells and platelets (pancytopenia), making the patient more susceptible to bleeding and bruising. The patient may feel tired, weak and short of breath. The patient also becomes more susceptible to infections.
• Reduced number of lymphocytes (a type of white blood cell), often caused by infection (lymphopenia).
• Low blood magnesium levels (hypomagnesaemia), which may cause fatigue, generalised weakness, muscle cramps, irritability and may lead to low blood calcium levels (hypocalcaemia), which may cause numbness and/or tingling in hands, feet or lips, muscle cramps, muscle weakness, pre-syncope, confusion.
• Low blood phosphate levels (hypophosphataemia), which may cause muscle weakness, irritability or confusion.
• High blood calcium levels (hypercalcaemia), which may cause slowed reflexes and weakness of skeletal muscles.
• High blood potassium levels, which may cause irregular heart rhythm.
• Low blood sodium levels, which may cause fatigue and confusion, muscle twitching, seizures (epileptic fits) or coma.
• High blood uric acid levels, which may lead to joint inflammation in the form of gout.
• Low blood pressure, which may cause dizziness or fainting.
• Pain or dryness in the mouth.
• Changes in taste sensation.
• Abdominal swelling.
• Feeling of disorientation.
• Depression.
• Loss of consciousness, fainting.
• Clouding of the eye (cataract).
• Kidney damage.
• Inability to pass urine.
• Abnormal liver function tests.
• Pelvic pain.
• Weight loss.

Uncommon (may affect up to 1 in 100 people):

• Stroke.
• Hepatitis, which may cause itching of the skin, yellowing of the skin and whites of the eyes (jaundice), pale-coloured stools, dark-coloured urine and abdominal pain.
• Tumour lysis syndrome – breakdown of tumour cells leading to release of toxic substances into the blood. This may lead to kidney problems.
• Hypothyroidism, which may cause symptoms such as fatigue, lethargy, muscle weakness, slow heart rate, weight gain.

Frequency not known (frequency cannot be estimated from available data):

• Rejection of a transplanted solid organ (such as heart or liver).

Reporting of adverse effects
If any adverse effects occur, including any not listed in this leaflet, tell your doctor, pharmacist or nurse. Adverse effects can be reported directly to the Department of Monitoring Adverse Drug Reactions at the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products: Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
Adverse effects can also be reported to the marketing authorisation holder.
Reporting adverse effects helps provide more information on the safety of this medicine.

5. How to store Pomalidomide Grindeks

Keep this medicine out of sight and reach of children.
Do not use this medicine after the expiry date stated on the blister pack and carton after EXP or Expiry date (EXP). The expiry date refers to the last day of the specified month.
No special storage conditions apply for this medicine.
Do not use Pomalidomide Grindeks if you notice any damage or signs of tampering with the packaging.
Medicines must not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.

6. Contents of the pack and other information

What Pomalidomide Grindeks contains
Pomalidomide Grindeks, 1 mg, hard capsules

• The active substance is pomalidomide. Each capsule contains 1 mg of pomalidomide.
• The other ingredients are: pregelatinized starch LM grade, maltodextrin, crospovidone, colloidal anhydrous silica, sodium stearyl fumarate.
• The capsule shell contains: gelatin, titanium dioxide (E171), colouring agents (iron oxide yellow (E172), iron oxide black (E172), brilliant black (E151), patent blue V (E131), azorubine (E122), brilliant blue FCF (E133)) and white printing ink (shellac, titanium dioxide (E171), sodium hydroxide, propylene glycol and povidone).

Pomalidomide Grindeks, 2 mg, hard capsules

• The active substance is pomalidomide. Each capsule contains 2 mg of pomalidomide.
• The other ingredients are: pregelatinized starch LM grade, maltodextrin, crospovidone, colloidal anhydrous silica, sodium stearyl fumarate.
• The capsule shell contains: gelatin, titanium dioxide (E171), colouring agents (yellow orange FCF (E110), brilliant black (E151), patent blue V (E131), azorubine (E122)) and white printing ink (shellac, titanium dioxide (E171), sodium hydroxide, propylene glycol and povidone).

Pomalidomide Grindeks, 3 mg, hard capsules

• The active substance is pomalidomide. Each capsule contains 3 mg of pomalidomide.
• The other ingredients are: pregelatinized starch LM grade, maltodextrin, crospovidone, colloidal anhydrous silica, sodium stearyl fumarate.
• The capsule shell contains: gelatin, titanium dioxide (E171), colouring agents (brilliant black (E151), patent blue V (E131), azorubine (E122), brilliant blue FCF (E133), erythrosine (E127)) and white printing ink (shellac, titanium dioxide (E171), sodium hydroxide, propylene glycol and povidone).

Pomalidomide Grindeks, 4 mg, hard capsules

• The active substance is pomalidomide. Each capsule contains 4 mg of pomalidomide.
• The other ingredients are: pregelatinized starch LM grade, maltodextrin, crospovidone, colloidal anhydrous silica, sodium stearyl fumarate.
• The capsule shell contains: gelatin, titanium dioxide (E171), colouring agents (brilliant blue FCF (E133), brilliant black (E151), patent blue V (E131), azorubine (E122), erythrosine (E127)) and white printing ink (shellac, titanium dioxide (E171), sodium hydroxide, propylene glycol and povidone).

What Pomalidomide Grindeks looks like and contents of the pack
Pomalidomide Grindeks, 1 mg are hard gelatin capsules of size 4 (approximately 14 mm × 5 mm) with a light grey body, printed with "P1" in white ink, and a dark blue, opaque cap.
Pomalidomide Grindeks, 2 mg are hard gelatin capsules of size 3 (approximately 16 mm × 6 mm) with an orange, opaque body, printed with "P2" in white ink, and a dark blue, opaque cap.
Pomalidomide Grindeks, 3 mg are hard gelatin capsules of size 2 (approximately 18 mm × 6 mm) with a light blue body, printed with "P3" in white ink, and a dark blue, opaque cap.
Pomalidomide Grindeks, 4 mg are hard gelatin capsules of size 1 (approximately 19 mm × 7 mm) with a blue, opaque body, printed with "P4" in white ink, and a dark blue, opaque cap.
The capsules are available in packs of 14 or 21 capsules (2 or 3 blisters per pack, with 7 capsules in each blister) or in packs of 14 x 1 or 21 x 1 capsules in a perforated, divisible blister pack, contained in a cardboard carton.
Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer
AS GRINDEKS
Krustpils iela 53,
Rīga, LV-1057,
Latvia
Tel.: +371 67083205
E-mail: [email protected]

This medicinal product is authorised in the European Economic Area countries under the following names:
Austria Pomalidomid Grindeks 1 mg, 2 mg, 3 mg, 4 mg Hartkapseln
Belgium Pomalidomide Grindeks 1 mg, 2 mg, 3 mg, 4 mg gélules
Bulgaria Помалидомид Гриндекс 1 mg, 2 mg, 3 mg, 4 mg твърди капсули
Pomalidomide Grindeks 1 mg, 2 mg, 3 mg, 4 mg hard capsules
Denmark Pomalidomid Grindeks
Estonia Pomalidomide Grindeks
Finland Pomalidomide Grindeks 1 mg, 2 mg, 3 mg, 4 mg kovat kapselit
France POMALIDOMIDE GRINDEKS 1 mg, gélule POMALIDOMIDE GRINDEKS 2 mg, gélule POMALIDOMIDE GRINDEKS 3 mg, gélule POMALIDOMIDE GRINDEKS 4 mg, gélule
Greece Pomalidomide/Grindeks
Spain Pomalidomida Grindeks 1 mg, 2 mg, 3 mg, 4 mg cápsula dura
Netherlands Pomalidomide Grindeks 1 mg harde capsules Pomalidomide Grindeks 2 mg harde capsules Pomalidomide Grindeks 3 mg harde capsules Pomalidomide Grindeks 4 mg harde capsules
Ireland Pomalidomide Grindeks 1 mg, 2 mg, 3 mg, 4 mg hard capsule
Lithuania Pomalidomide Grindeks 1 mg, 2 mg, 3 mg, 4 mg kietosios kapsulės
Latvia Pomalidomide Grindeks 1 mg, 2 mg, 3 mg, 4 mg cietās kapsulas
Germany Pomalidomid Grindeks 1 mg, 2 mg, 3 mg, 4 mg Hartkapseln
Norway Pomalidomide Grindeks
Poland Pomalidomide Grindeks
Portugal Pomalidomida Grindeks 1 mg, 2 mg, 3 mg, 4 mg cápsula
Czech Republic Pomalidomide Grindeks
Romania Pomalidomidă Grindeks 1 mg capsule Pomalidomidă Grindeks 2 mg capsule Pomalidomidă Grindeks 3 mg capsule Pomalidomidă Grindeks 4 mg capsule
Slovakia Pomalidomid Grindeks 1 mg tvrdé kapsuly Pomalidomid Grindeks 2 mg tvrdé kapsuly Pomalidomid Grindeks 3 mg tvrdé kapsuly Pomalidomid Grindeks 4 mg tvrdé kapsuly
Slovenia Pomalidomid Grindeks 1 mg, 2 mg, 3 mg, 4 mg trde kapsule
Sweden Pomalidomide Grindeks 1 mg, 2 mg, 3 mg, 4 mg hårda kapslar
Hungary Pomalidomide Grindeks 1 mg, 2 mg, 3 mg, 4 mg kemény kapszula
Italy Pomalidomide Grindeks